JP2018535404A5 - - Google Patents

Download PDF

Info

Publication number
JP2018535404A5
JP2018535404A5 JP2018516740A JP2018516740A JP2018535404A5 JP 2018535404 A5 JP2018535404 A5 JP 2018535404A5 JP 2018516740 A JP2018516740 A JP 2018516740A JP 2018516740 A JP2018516740 A JP 2018516740A JP 2018535404 A5 JP2018535404 A5 JP 2018535404A5
Authority
JP
Japan
Prior art keywords
hgdf
cancer
detection kit
level
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018516740A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018535404A (ja
JP6858181B2 (ja
Filing date
Publication date
Priority claimed from GBGB1517527.6A external-priority patent/GB201517527D0/en
Priority claimed from GBGB1607800.8A external-priority patent/GB201607800D0/en
Application filed filed Critical
Priority claimed from PCT/EP2016/073519 external-priority patent/WO2017055612A1/en
Publication of JP2018535404A publication Critical patent/JP2018535404A/ja
Publication of JP2018535404A5 publication Critical patent/JP2018535404A5/ja
Application granted granted Critical
Publication of JP6858181B2 publication Critical patent/JP6858181B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018516740A 2015-10-02 2016-09-30 免疫チェックポイントブロッカーを用いる治療の臨床アウトカムを予測するための診断マーカーとしてのgdf−15 Active JP6858181B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1517527.6A GB201517527D0 (en) 2015-10-02 2015-10-02 GDF-15 as a diagnosis marker to predict the clinical outcome of a treatment with immune checkpoint blockers
GB1517527.6 2015-10-02
GBGB1607800.8A GB201607800D0 (en) 2016-04-29 2016-04-29 GDF-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
GB1607800.8 2016-04-29
PCT/EP2016/073519 WO2017055612A1 (en) 2015-10-02 2016-09-30 Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers

Publications (3)

Publication Number Publication Date
JP2018535404A JP2018535404A (ja) 2018-11-29
JP2018535404A5 true JP2018535404A5 (enExample) 2021-01-21
JP6858181B2 JP6858181B2 (ja) 2021-04-14

Family

ID=57123979

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018516740A Active JP6858181B2 (ja) 2015-10-02 2016-09-30 免疫チェックポイントブロッカーを用いる治療の臨床アウトカムを予測するための診断マーカーとしてのgdf−15

Country Status (10)

Country Link
US (3) US11262360B2 (enExample)
EP (2) EP3356827B1 (enExample)
JP (1) JP6858181B2 (enExample)
KR (1) KR102621034B1 (enExample)
AU (1) AU2016333538B2 (enExample)
CA (1) CA3000290C (enExample)
DK (1) DK3356827T3 (enExample)
ES (1) ES2968226T3 (enExample)
FI (1) FI3356827T3 (enExample)
WO (1) WO2017055612A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013322628B2 (en) * 2012-09-26 2017-03-02 Julius-Maximilians-Universitat Wurzburg Monoclonal antibodies to growth and differentiation factor 15 (GDF-15)
US10509045B2 (en) 2015-05-29 2019-12-17 University Of Florida Research Foundation, Incorporated Methods for diagnosing Huntington's disease
EP3356827B1 (en) 2015-10-02 2023-12-06 Julius-Maximilians-Universität Würzburg Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
US10940161B2 (en) 2016-04-04 2021-03-09 University Of Florida Research Foundation, Incorporated Manipulation of EIF3 to modulate repeat associated non-ATG (RAN) translation
KR102433503B1 (ko) 2016-05-24 2022-08-18 노보 노르디스크 에이/에스 Mic-1 화합물 및 이것의 사용
EP3612190A4 (en) 2017-04-17 2021-01-20 University of Florida Research Foundation, Incorporated REGULATION OF RAN TRANSLATION THROUGH PKR AND EIF2A-P WAYS
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Mic-1化合物及其用途
EP3688020A4 (en) * 2017-09-25 2021-07-14 University of Florida Research Foundation, Incorporated IMMUNOASSAYS FOR DETECTION OF RAN PROTEINS
JP2022523564A (ja) 2019-03-04 2022-04-25 アイオーカレンツ, インコーポレイテッド 機械学習を使用するデータ圧縮および通信
KR102164432B1 (ko) 2019-09-18 2020-10-13 한국과학기술원 Dna 메틸화 변이를 이용한 면역항암치료 반응성 예측방법
AU2020348916B2 (en) 2019-09-20 2025-12-18 University Of Florida Research Foundation, Incorporated Detection of antibodies against RAN proteins from serum and tissue lysates
WO2021072187A2 (en) 2019-10-10 2021-04-15 University Of Florida Research Foundation, Incorporated Ran proteins as biomarkers in cag/ctg expansion disorders
KR102238912B1 (ko) 2020-05-27 2021-04-12 한국과학기술원 Dna 메틸화 변이 및 종양 변이 부담을 이용한 면역항암치료 반응성 예측방법
CN112162097B (zh) * 2020-07-24 2022-04-01 广州医科大学 Gdf1作为评估pd-1单抗治疗效果的生物标志物
LT4243928T (lt) 2020-11-10 2026-06-10 Catalym Gmbh Anti-gdf15 antikūnas ir dozavimo režimas, skirtas vėžio gydymui
CN112698042A (zh) * 2020-12-17 2021-04-23 北京赛诺浦生物技术有限公司 检测人生长分化因子-15的荧光免疫层析试纸条及其制备方法和应用
CN113252905A (zh) * 2021-05-12 2021-08-13 北京赛诺浦生物技术有限公司 人生长分化因子-15磁微粒化学发光检测试剂盒及其应用
IL310535A (en) * 2021-08-10 2024-03-01 Byomass Inc Anti-gdf15 antibodies, compositions and uses thereof
CN113702647B (zh) * 2021-08-31 2024-03-15 普十生物科技(北京)有限公司 人生长分化因子15即时检测试剂盒、其制备方法及其应用
KR20230046264A (ko) 2021-09-29 2023-04-05 (주)펜타메딕스 Line-1의 dna 메틸화 변이를 이용한 면역항암치료 반응성 예측방법
CN115831306A (zh) * 2023-02-23 2023-03-21 北京康博众联电子科技有限公司 一种数据分析装置、方法及计算机存储介质
CN116462757A (zh) * 2023-03-24 2023-07-21 科兴生物制药股份有限公司 Gdf15的单域抗体及其应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6455677B1 (en) 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
US6465181B2 (en) 1999-03-25 2002-10-15 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
CA2372119A1 (en) 1999-05-17 2000-11-23 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Und Zum Vertrie B Von Pharmaka Mbh Neuroprotective properties of gdf-15, a novel member of the tgf-.beta. superfamily
US7141661B2 (en) 2000-09-08 2006-11-28 The United States Of America As Represented By The Department Of Health And Human Services Non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties
ES2689328T3 (es) 2004-01-07 2018-11-13 Novartis Vaccines And Diagnostics, Inc. Anticuerpo monoclonal M-CSF-específico y usos del mismo
DK2441466T3 (da) 2004-04-13 2014-10-27 St Vincents Hosp Sydney MIC-1-inhiberende middel
US20070128636A1 (en) 2005-12-05 2007-06-07 Baker Joffre B Predictors Of Patient Response To Treatment With EGFR Inhibitors
US20100278843A1 (en) 2007-08-16 2010-11-04 St. Vincent's Hospital Sydney Limited Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
CN101896192A (zh) 2007-10-09 2010-11-24 圣文森特医院悉尼有限公司 一种通过去除或灭活巨噬细胞抑制因子-1而治疗恶病质的方法
WO2009150256A1 (en) 2008-06-13 2009-12-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Markers for predicting response and survival in anti-egfr treated patients
CA2737636A1 (en) 2008-09-29 2010-04-01 Roche Glycart Ag Antibodies against human il17 and uses thereof
EP2209003A1 (en) * 2009-01-16 2010-07-21 F. Hoffmann-Roche AG Means and methods for differentiating between fibrosis and cirrhosis
US7736861B1 (en) 2009-10-19 2010-06-15 Aveo Pharmaceuticals, Inc. Tivozanib response prediction
US20120309697A1 (en) 2009-10-28 2012-12-06 Samuel Norbert Breit Methods of diagnosing and prognosing colonic polyps
US9212221B2 (en) 2010-03-03 2015-12-15 Detroit R & D, Inc. Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
CN105859889B (zh) 2010-11-17 2020-01-07 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
WO2013012648A1 (en) 2011-07-15 2013-01-24 Emory University Gdf15 in diagnostic and therapeutic applications
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
CN102321173B (zh) 2011-08-12 2013-04-03 中国医学科学院肿瘤研究所 人源化巨噬细胞抑制因子1单克隆抗体及其应用
EP2565262A1 (en) 2011-08-31 2013-03-06 VTU Holding GmbH Protein expression
KR20140125803A (ko) 2012-01-26 2014-10-29 암젠 인크 성장 분화 인자 15(gdf-15) 폴리펩타이드들
AU2013322628B2 (en) * 2012-09-26 2017-03-02 Julius-Maximilians-Universitat Wurzburg Monoclonal antibodies to growth and differentiation factor 15 (GDF-15)
ES3066738T3 (en) 2012-12-21 2026-05-14 Aveo Pharmaceuticals Inc Anti-gdf15 antibodies
US11021752B2 (en) * 2013-03-15 2021-06-01 Myriad Genetics, Inc. Genes and gene signatures for diagnosis and treatment of melanoma
JP2015078138A (ja) 2013-10-15 2015-04-23 株式会社ニックス 小動物防除性樹脂組成物
WO2015108907A2 (en) * 2014-01-14 2015-07-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
ES2712201T3 (es) * 2014-01-28 2019-05-09 Hoffmann La Roche Biomarcadores para la evaluación de riesgos y la monitorización del tratamiento en pacientes de insuficiencia cardíaca que han recibido terapia guiada por el péptido natriurético de tipo B
PT3134123T (pt) 2014-02-21 2021-03-22 Nektar Therapeutics India Pvt Ltd Agonistas seletivos de il-2rbeta em combinação com um anticorpo anti-ctla-4 ou um anticorpo anti-pd-1
PT3653644T (pt) 2014-03-26 2023-12-19 Univ Wuerzburg J Maximilians Anticorpos monoclonais do fator de crescimento e diferenciação 15 (gdf-15) e suas utilizações para o tratamento da caquexia cancerosa e do cancro
EP3851122A1 (en) 2014-09-25 2021-07-21 Aveo Pharmaceuticals Inc. Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent
GB201517528D0 (en) 2015-10-02 2015-11-18 Julius Maximillians Universitãt Würzburg GDF-15 as a diagnosis marker for melanoma
KR102722730B1 (ko) 2015-10-02 2024-10-25 율리우스-막시밀리안스 우니버지태트 뷔르츠부르크 인간 증식 및 분화 인자 15 (gdf-15)의 저해제와 면역 체크포인트 차단제를 이용한 병용 요법
EP3356827B1 (en) 2015-10-02 2023-12-06 Julius-Maximilians-Universität Würzburg Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
CN112912395B (zh) 2018-08-20 2024-08-23 辉瑞公司 抗gdf15抗体、组合物和使用方法

Similar Documents

Publication Publication Date Title
FI3356827T3 (fi) GDF-15 diagnostisena markkerina immuunivasteen vapauttajilla annetun hoidon hoitovasteen ennustamiseksi
Sharma et al. Ultrasensitive direct impedimetric immunosensor for detection of serum HER2
JP2015533788A5 (enExample)
JP2017518366A5 (enExample)
ES2641294T3 (es) Nuevo anticuerpo para el diagnóstico y/o el pronóstico del cáncer
JP6484562B2 (ja) 可溶性gpc3タンパク質の測定方法
JP2017524725A5 (enExample)
JP2014524744A5 (enExample)
EP3349011B1 (en) Liver cancer test method
NZ716369A (en) Anti-ox40 antibodies and methods of using the same
Qu et al. A rapid and highly sensitive portable chemiluminescent immunosensor of carcinoembryonic antigen based on immunomagnetic separation in human serum
RU2015103228A (ru) Антитела против тау
JP2015502547A5 (enExample)
JP2011530514A5 (enExample)
JP2018520668A5 (enExample)
RU2017119009A (ru) Анализы для обнаружения субпопуляций иммунных т-клеток и способы их применения
Weeraratne et al. Development of a biosensor-based immunogenicity assay capable of blocking soluble drug target interference
RU2016116773A (ru) Способ выявления опухоли поджелудочной железы, антитела и набор для выявления опухоли поджелудочной железы
JP2020510409A5 (enExample)
JP2019532633A5 (enExample)
JP2015527365A5 (enExample)
JP2015531768A5 (enExample)
Yan et al. A novel rapid quantitative method reveals stathmin‐1 as a promising marker for esophageal squamous cell carcinoma
JP2016516008A5 (enExample)
JP2017532577A5 (enExample)